Sol-Gel Technologies and Beimei Pharma Collaborate to Commercialize Twyneo for Treating Acne Vulgaris
Shots:
- Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical to commercialize Twyneo for treating acne vulgaris across mainland China, Hong Kong, Macau, Taiwan & Israel
- As per the agreement, Beimei gains exclusive commercialization rights to Twyneo across those regions. Sol-Gel is entitled to receive an aggregate of $10M which includes upfront and milestones plus up to $5M net-sales-based royalty
- The company also anticipates future collaborations for the commercialization of both Twyneo and Epsolay across other regions
Ref: Sol-Gel Technologies | Image: Sol-Gel Technologies
Related News:- Sol-Gel Technologies' Twyneo (tretinoin/benzoyl peroxide) Cream Receives the US FDA's Approval for the Treatment of Acne Vulgaris
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.